In terms of best-funded companies overall,…
Epstein-Barr virus: Trigger and driver of multiple sclerosis?
Recent research has indicated a link between Epstein-Barr virus (EBV) and multiple sclerosis (MS), with some researchers going as far as to say that EBV might be a potential trigger of MS. However, it remains unclear whether the virus also drives the progression of the disease. Current treatments focus largely on moderating inflammation. In this article, we expand on the hypothesized correlation between MS and EBV, and underscore the need to consider antiviral protection in drug development.
BackgroundMultiple sclerosis. MS is an unpredictable and debilitating neurological autoimmune disease that turns the body’s immune system against itself, …
Natalizumab and PML: The complex dance of benefit and risk for MS
Biogen’s Tysabri (natalizumab), the first humanized monoclonal antibody for multiple sclerosis (MS), sparked optimism among MS patients following its FDA approval in 2004. The drug offered significant benefits, reducing relapses for patients resistant to other treatments. This was a significant milestone in the treatment of MS, but the journey of natalizumab and PML soon took a concerning turn.
Within a year, alarming reports surfaced: A number of patients were developing progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection. The suspected culprit? Natalizumab’s immunomodulatory effect, which suppressed the immune cells fighting the JC (John Cunningham) virus…